EUVIMEDOpdag EUVIMED
Randomisierte kontrollierte Studie

Pharmacokinetics and Pharmacodynamics of Burixafor Hydrobromide (GPC‐100), a Novel C‐X‐C Chemokine Receptor 4 Antagonist and Mobilizer of Hematopoietic Stem/Progenitor Cells, in Mice and Healthy Subjects

Devki D Sukhtankar, Li-Wen Chang, Cheng-Yuan Tsai, Pina M Cardarelli, Niña G Caculitan

Clinical Pharmacology in Drug Development · 2023-11 · 12 (11) · 1114-1120

DOI: 10.1002/cpdd.1302 ↗

At a glance

Randomisierte kontrollierte Studie in Clinical Pharmacology in Drug Development, published online on 2023-08-04. Written by Devki D Sukhtankar and 4 co-authors. Institution: GPCR Therapeutics, Inc., Seoul, South Korea. Major MEDLINE topics: Hematopoietic Stem Cell Mobilization, Hematopoietic Stem Cell Transplantation. Cited 9 times so far (Crossref); 5 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Adequate mobilization of hematopoietic stem cells (HSCs), especially CD34 + cells, is necessary for stem cell transplantation in patients with hematological malignancies or autoimmune diseases. Burixafor is an inhibitor of the C‐X‐C Chemokine Receptor 4 that disrupts the C‐X‐C motif chemokine 12 (CXCL12)/CXCR4 axis in the bone marrow, releasing HSCs into circulation. In mice, a single intravenous dose of burixafor was rapidly absorbed (time to maximum concentration, 5 minutes) and increased peripheral white blood cell counts within 30 minutes. Additionally, burixafor was administered to 64 healthy subjects in a randomized, double‐blind, placebo‐controlled, single‐ascending‐dose study to evaluate safety, pharmacokinetics, and pharmacodynamics. Subjects received burixafor intravenous doses ranging from 0.10 to 4.40 mg/kg in 8 cohorts. Single doses were generally safe and well tolerated. Gastrointestinal events were reported at doses of 2.24 mg/kg or greater. Exposure (maximum concentration and area under the concentration–time curve) increased in an approximately dose‐proportional manner. Time to maximum concentration occurred with a median of 0.26–0.30 hours that was not dose proportional. As expected, white blood cell, CD133 + cell, and CD34 + cell concentrations generally increased with the increases in burixafor dose from 0.10 to 3.14 mg/kg. At maximal levels, the CD34 + cell counts increased 3‐ to 14‐fold from baseline levels. These results provide support for continued clinical development of burixafor.

Subjects

MeSH terms (MEDLINE)

Hematopoietic Stem Cell MobilizationHematopoietic Stem Cell TransplantationHumansAnimalsMiceHealthy VolunteersHematopoietic Stem CellsReceptors, Chemokine

Author keywords

CXCR4 inhibitorburixaforpharmacodynamicspharmacokineticssafetystem cell mobilization

Substances

Receptors, Chemokine

Authors and institutions

  • GPCR Therapeutics, Inc., Seoul, South Korea.
  • GPCR Therapeutics USA, Redwood City, CA, USA.
  • TaiGen Biotechnology Col Ltd, Taipei, Taiwan.

Cite

APA

Sukhtankar, D. D., Chang, L. W., Tsai, C. Y., Cardarelli, P. M., & Caculitan, N. G. (2023). Pharmacokinetics and Pharmacodynamics of Burixafor Hydrobromide (GPC‐100), a Novel C‐X‐C Chemokine Receptor 4 Antagonist and Mobilizer of Hematopoietic Stem/Progenitor Cells, in Mice and Healthy Subjects. Clinical Pharmacology in Drug Development, 12(11), 1114-1120. https://doi.org/10.1002/cpdd.1302

Vancouver

Sukhtankar DD, Chang LW, Tsai CY, Cardarelli PM, Caculitan NG. Pharmacokinetics and Pharmacodynamics of Burixafor Hydrobromide (GPC‐100), a Novel C‐X‐C Chemokine Receptor 4 Antagonist and Mobilizer of Hematopoietic Stem/Progenitor Cells, in Mice and Healthy Subjects. Clinical Pharmacology in Drug Development. 2023;12(11):1114-1120. doi:10.1002/cpdd.1302

BibTeX
@article{Sukhtankar2023,
  author = {Sukhtankar, Devki D and Chang, Li-Wen and Tsai, Cheng-Yuan and Cardarelli, Pina M and Caculitan, Niña G},
  title = {Pharmacokinetics and Pharmacodynamics of Burixafor Hydrobromide (GPC‐100), a Novel C‐X‐C Chemokine Receptor 4 Antagonist and Mobilizer of Hematopoietic Stem/Progenitor Cells, in Mice and Healthy Subjects},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2023},
  volume = {12},
  number = {11},
  pages = {1114--1120},
  doi = {10.1002/cpdd.1302}
}
Start for free →